Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
July 28 2022 - 8:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced a presentation at the 3rd Annual Cytokine-Based
Drug Development Summit. The presentation highlights Equillium’s
multi-cytokine inhibitor technology and platform, and applications
of cytokine technology beyond oncology. Data on the platform,
including the lead tri-specific inhibitory agent, EQ101, were
presented by Dr. Stephen Connelly, co-founder and chief scientific
officer of Equillium. The Summit is taking place at the Wyndham
Boston Beacon Hill and runs July 26 – 29.
“Cytokines play a critical role in inflammation, autoimmunity
and cancer, and modulating their activity has become central to how
we think about developing innovative treatments for these
diseases,” said Dr. Connelly. “This Summit is a great forum to
showcase the pre-clinical, translational and clinical data
supporting EQ101 a novel, first-in-class tri-specific cytokine
inhibitor in the treatment of neoplastic and inflammatory skin
diseases. This data also provides translational support for our
upcoming clinical catalysts: a planned Phase 2 clinical study of
EQ101 in alopecia areata and a Phase 1 SAD/MAD study of EQ102 – a
novel first-in-class bi-specific cytokine inhibitor – in normal
healthy volunteers, as well as celiac disease patients. Both
studies are scheduled to commence later this year.”
The presentation, titled “Targeting Biological Synergy At the
Receptor Level – Multi-specific
Cytokine Inhibitors”, focuses on the design and development of
multi-specific cytokine inhibitors and the importance of targeting
biological synergy to optimize therapeutic outcomes. Validation of
this approach is demonstrated with EQ101, a novel, first-in-class
tri-specific cytokine inhibitor that can selectively target and
potently inhibit the key common yc family cytokines of IL-2, IL-9
and IL-15. Translational studies have shown that EQ101 inhibits
these cytokines and exhibits potent activity in suppressing
multiple lymphoproliferative or leukemic T-cell lines. Furthermore,
clinical efficacy and a favorable safety profile has been
demonstrated in patients with refractory cutaneous T cell lymphoma.
In addition to applications in oncology, translational studies of
EQ101 in an inflammatory skin disease model have highlighted the
potential to treat skin diseases such as atopic dermatitis,
alopecia areata and vitiligo. Selectively targeting these key
cytokines at a receptor level may provide a more potent and
selective approach than direct JAK inhibition.
The presentation is available under the technology section of
the company website on the presentations page.
About Multi-Cytokine Platform: EQ101 & EQ102
Our proprietary multi-cytokine platform (MCP) generates
rationally designed composite peptides that selectively block key
cytokines at the shared receptor level targeting pathogenic
cytokine redundancies and synergies while preserving non-pathogenic
signaling. This approach provides multi-cytokine inhibition at the
receptor level and is expected to avoid the broad
immuno-suppression and off-target safety liabilities that may be
associated with other therapeutic classes, such as JAK inhibitors.
Many immune-mediated diseases are driven by the same combination of
dysregulated cytokines, and we believe identifying the key
cytokines for these diseases will allow us to target and develop
customized treatment strategies for multiple autoimmune and
inflammatory diseases.
Current MCP assets include EQ101, a first-in-class, tri-specific
inhibitor of IL-2, IL-9 and IL-15, and EQ102, a first-in-class,
selective inhibitor of IL-15 and IL-21.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel immunomodulatory assets targeting
immuno-inflammatory pathways. Itolizumab, a first-in-class
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells,
is currently in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for
patients with lupus/lupus nephritis. EQ101, a first-in-class
tri-specific cytokine inhibitor that selectively targets IL-2,
IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling
patients in an alopecia areata study in the second half of 2022.
EQ102, a bi-specific cytokine inhibitor that selectively targets
IL-15 and IL-21, is ready for clinical development and expected to
begin enrolling patients in a Phase 1 study anticipated to include
normal healthy volunteers and celiac disease patients in the second
half of 2022.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of the Company’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to statements regarding the potential
benefit of EQ101 and EQ102, Equillium’s plans and expected timing
for developing EQ101 and EQ102 including the expected timing of
initiating, completing and announcing further results from Phase 2
and Phase 1 studies, respectively, the potential for any of
Equillium’s ongoing or planned clinical studies to show safety or
efficacy, Equillium’s anticipated timing of regulatory review and
feedback, and Equillium’s plans and expected timing for developing
its product candidates and potential benefits of its product
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: uncertainties related to the
abilities of the leadership team to perform as expected;
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; potential delays in the
commencement, enrollment and completion of clinical studies and the
reporting of data therefrom; the risk that studies will not be
completed as planned; Equillium’s plans and product development,
including the initiation and completion of clinical studies and the
reporting of data therefrom; whether the results from clinical
studies will validate and support the safety and efficacy of
Equillium’s product candidates; changes in the competitive
landscape; uncertainties related to Equillium’s capital
requirements; and having to use cash in ways or on timing other
than expected and the impact of market volatility on cash reserves.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and elsewhere in Equillium's
filings and reports, which may be accessed for free by visiting
EDGAR on the SEC web site at http://www.sec.gov and on the
Company’s website under the heading “Investors.” Investors should
take such risks into account and should not rely on forward-looking
statements when making investment decisions. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Equillium undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220728005227/en/
Investor & Media Contact Michael Moore Vice
President, Investor Relations & Corporate Communications
619-302-4431 ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024